NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

DVAX

Dynavax Technologies Corporation NASDAQ Capital Market
$9.25
Open: $9 High: $9.4 Low: $8.48 Close: $9.21
Range: 2021-05-06 - 2021-05-07
Volume: 3,329,515
Market: Closed
Powered by Finage Stock APIDelayed data
DVAX
Dynavax Technologies Corporation 2929 Seventh Street Berkeley CA, 94710-2753 http://www.dynavax.com
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor ("TLR") stimulation.
  • CEO: Eddie Gray
  • Employees: 192
  • Sector: Healthcare
  • Industry: Biotechnology
DVAX News
Latest news about the DVAX
  • Dynavax Technologies (DVAX) Beats Q1 Earnings and Revenue Estimates

    Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 37.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    View More →
  • Dynavax Announces First Quarter 2021 Financial Results

    Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the first quarter of 2021.

    View More →
  • Dynavax Technologies Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Dynavax Technologies Corp. (NASDAQ:DVAX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time.

    View More →
  • Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 148,500 shares of Dynavax common stock as inducements to seven newly-hired employees in connection with commencement of employment with the Company.

    View More →
  • What Type Of Shareholders Own The Most Number of Dynavax Technologies Corporation (NASDAQ:DVAX) Shares?

    If you want to know who really controls Dynavax Technologies Corporation ( NASDAQ:DVAX ), then you'll have to look at...

    View More →
  • Will Dynavax Technologies (DVAX) Report Negative Earnings Next Week? What You Should Know

    Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    View More →
  • HEPLISAV-B Post-Marketing Observational Study Results Presented at 2021 Annual Conference on Vaccinology Research (ACVR)

    Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the results of the post-marketing study assessing the rates of occurrence of acute myocardial infarction (AMI) in persons receiving HEPLISAV-B compared with Engerix-B. The results were selected for an oral presentation at the National Foundation for Infectious Diseases (NFID) 2021 Annual Conference on Vaccinology Research (ACVR), a premier forum for the exchange of scientific and clinical knowledge in vaccinology, being held virtually April 26-27, 2021.

    View More →
  • Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

    Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report first quarter 2021 financial results on Thursday, May 6, 2021, after the U.S. financial markets close.

    View More →
  • Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax's CpG 1018™ Adjuvant

    Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced Valneva SE has initiated a pivotal Phase 3 clinical trial for its inactivated, COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG 1018 adjuvant. The Phase 3 trial "Cov-Compare", (VLA2001-301), will compare Valneva's SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca's conditionally approved vaccine, Vaxzevria, in a comparative immunogenicity trial.

    View More →
  • Two HEPLISAV-B Abstracts Selected for Oral Presentation at the 2021 Annual Conference on Vaccinology Research (ACVR)

    Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that two HEPLISAV-B abstracts have been selected for oral presentation at the 2021 Annual Conference on Vaccinology Research (ACVR).

    View More →
  • Why Dynavax Stock Jumped Today

    What happened Shares of Dynavax Technologies (NASDAQ: DVAX) were jumping 7.1% higher as of 3:38 p.m. EDT on Thursday. The gain came after Valneva reported positive initial results from the first part of a phase 1/2 clinical study evaluating its COVID-19 vaccine candidate VLA2001.

    View More →
  • Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised)

    Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.

    View More →
  • Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

    The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

    View More →
  • Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data

    Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.

    View More →
  • Biden advances timeline for COVID vaccine eligibility as experts warn Americans, ‘the war is not yet won’

    The U.S. COVID-19 vaccine push got another boost Tuesday, with President Joe Biden expected to announce that all Americans will be eligible for a jab by April 19, moving up an earlier deadline of May 1.

    View More →
  • Dynavax’s CpG 1018 Used In Valneva’s COVID-19 Vaccine Reports Positive Results

    Dynavax Technologies reported positive results in 153 adults aged 18 years to 55 years for Part A of the Phase-1 clinical trial of Valneva SE’s inactivated COVID-19 vaccine candidate, VLA2001, that uses Dynavax’s CpG 1018 adjuvant. An adjuvant is a substance that improves the efficacy of a vaccine and enhances the response of the immune system to the presence of an antigen. Shares of the biopharma company, Dynavax Technologies (DVAX), were up 3.2% in pre-market trading on April 6. Dynavax’s CEO, Ryan Spencer said, “We are excited to see the positive results Valneva has generated with their inactivated vaccine using Dynavax’s CpG 1018 adjuvant. We believe the effect delivered by our CpG 1018 adjuvant combined with Valneva’s existing manufacturing process for whole virus inactivated vaccines will result in an important option in the global fight against COVID-19.” “This platform has potential to allow rapid modifications to the vaccine as needed to address variants using Valneva’s existing manufacturing process,” Spencer added. (See Dynavax Technologies Corp stock analysis on TipRanks) Valneva plans to commence a pivotal Phase 3 clinical trial by the end of April this year subject to regulatory approvals based on these positive results. Valneva also reported that “VLA2001 was generally safe and well tolerated across all dose groups tested and was highly immunogenic with a seroconversion rate for S-protein binding IgG antibodies of 100% in the high dose group.” Last month, H.C Wainwright analyst Edward White reiterated a Buy and a price target of $16 (62.6% upside potential) on the stock. White said in a note to investors, “Dynavax currently has four collaborations in place that are focused on developing COVID-19 vaccines. It expects CpG 1018 adjuvant sales could be in the range of $40-60M for 1Q21.” The rest of the Street is bullish about the stock with a Strong Buy consensus rating. That’s based on 3 analysts suggesting a Buy. The average analyst price target of $16.67 implies around 69.4% upside potential to current levels. According to TipRanks data, financial Bloggers are 88% bullish on DVAX stocks based on the opinions of 9 bloggers. Related News: Cidara Inks Licensing and Collaboration Deal With J&J’s Janssen For Influenza Antiviral CD388 Ares Management Launches 9.5M Offering Of Class A Shares United Therapeutics Receives FDA Approval For Tyvaso Therapy; Shares Pop 15% More recent articles from Smarter Analyst: Sorrento Inks Deal To Buy ACEA Therapeutics; Shares Gain 3% HTG Molecular Drops Over 7% As 1Q Revenue Forecast Lags Estimates Digital Realty Opens Its Largest Singapore Data Center OSI Systems’ Spacelabs Gains $4M Order; Street Remains Bullish

    View More →
  • Valneva's COVID-19 Vaccine Candidate Using Dynavax's Adjuvant Shows Positive Interim Results

    Dynavax Technologies Corporation (NASDAQ: DVAX) has announced that Valneva SE reported initial results from Part A of the Phase 1/2 trial evaluating Valneva's COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG 1018 adjuvant. The trial is being conducted in 153 healthy adults aged 18 to 55 years. VLA2001 was generally safe and well-tolerated across all dose groups tested and was highly immunogenic with a seroconversion rate for S-protein binding IgG antibodies of 100% in the high dose group. The IgG antibody response was highly correlated with neutralization titers in a micro-neutralization assay. Valneva plans to initiate a pivotal, comparative immunogenicity Phase 3 clinical trial with the high dose formulation by the end of next month. Dynavax developed CpG 1018 adjuvant to provide an increased vaccine immune response. CpG 1018 adjuvant is used in Hepatitis B Vaccine approved by the FDA and the European Medicines Agency. Price Action: DVAX shares are trading 4.4% higher at $10.28 on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaDynavax Stock Is Trading Higher As Adjuvanted COVID-19 Vaccine Trial Moves Forward© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • French vaccine maker Valneva to launch Phase 3 trial of COVID vaccine it's making with Dynavax after positive results

    Dynavax Technologies Corp. said Tuesday that French vaccine maker Valneva plans to commence a Phase 3 trial of its inactivated COVID-19 vaccine candidate, VLA2001, with Dynavax's CpG 1018(TM) adjuvant by the end of April after achieving positive results in a Phase 1/2 trial. The trial involved 153 healthy adults aged 18 to 55 years old and found the combination was safe and highly immunogenic. The group giving the highest dose produced antibodies and T cells and only showed mild to moderate adverse events. "We believe the effect delivered by our CpG 1018 adjuvant combined with Valneva's existing manufacturing process for whole virus inactivated vaccines will result in an important option in the global fight against COVID-19," Dynavax Chief Executive Ryan Spencer said in a statement. Dynavax shares were up 2.6% premarket and have gained 121% in the year to date, while the S&P 500 has gained 8.6%.

    View More →
  • Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant

    Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG 1018™ adjuvant in 153 healthy adults aged 18 to 55 years. Based on these results, Valneva plans to commence a pivotal Phase 3 clinical trial by the end of April 2021, subject to regulatory approval.

    View More →
  • Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate

    Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company developing transformative biologics such as vaccines and therapeutics for the world's most debilitating diseases, and Dynavax Technologies Corporation (Dynavax, Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the first participants have been dosed in Clover's SPECTRA trial (Study Evaluating Protective-Efficacy and Safety of Clover's Trimeric Recombinant Protein-based and Adjuvanted COVID-19 Vaccine), a global Phase 2/3 clinical trial evaluating the efficacy, safety and immunogenicity of Clover's protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum.

    View More →